My research investigates the effects of beta-carotene and retinol palmitate, two different forms of Vitamin A, on reducing the effects of neurodegeneration caused by beta-amyloid aggregation, one of the two leading hypotheses for Alzheimer’s disease. My model transgenic organism, Caenorhabditis elegans (strain CL4176), paralyzes when upshifted from 16℃ to 25℃ from beta-amyloid aggregation. I hypothesized that the paralysis rates in my worms would decrease after exposure to beta-carotene and retinol palmitate, with the high retinol palmitate group showing the most drastic effect. My methods included a control (untreated), two beta carotene experimental (4.84 x 10-6 and 9.68 x 10-6 μg), and two retinol palmitate (2.42 x 10-6 μg and 4.84 x 10-6 μg), experimental groups, each of which contained 3-4 trials, each with 4 plates of 50 age-synchronized worms to control for age variability. All plates were exposed to the respective compound and concentration 24 hours after synchronization, upshifted, and paralysis rates were measured by counting the paralyzed worms in each plate. Results were analyzed by testing for significance using a one-way ANOVA test (p < 0.01), and both dosages of both compounds were shown to be statistically significant from the control. My results showed that both beta-amyloid and retinol palmitate reduced the paralysis rates by an average of 6.87% and 7.73% in the beta-carotene and retinol palmitate low dosage groups, respectively, and 14.00% and 14.37% in the high dosage experimental groups, which supported my hypothesis.